can you take semaglutide with tirzepatide vs. Semaglutide: Which Is Better For ? Tirzepatide vs Semaglutide: Key Differences

Due to their lack of association with hypoglycemia, positive effects on satiety and weight loss, and infrequency of administration, these GLP-1 analogues are now the first injectable medication of choice indicated by ADA guidelines for type-2 diabetics

Asuno GLP-1 weight-loss gummies: top overall pick Asuno claims the top spot because it meets every science-first criterion without giving up taste or label clarity

Its major patents have recently expired: in the US and Europe, the patent ran out at the end of 2023, after which generic versions appeared in 2024

Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono

Tirzepatide, on the other hand, is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist